Funding for Assay Development and Screening
IGNITE: Assay Development and Neurotherapeutic Agent Identification
- Support: 3-year R61/R33 to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential neurotherapeutic agents
- Participating Institutes: NINDS, NCCIH
- To apply: PAR-21-124
Funding for Preclinical Proof-of-Concept
Drug Discovery for Nervous System Disorders
- Participating Institutes: NIMH, NIA, NIAAA, NIDA
- To apply: PAR-19-147 (R01), PAR-19-146 (R21)
IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
- Support: 3-year R61/R33 to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development
- Participating Institute: NINDS
- To apply: PAR-21-122
Funding for Translational Model Development
IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery
- Support: 3- year R61/R33 to support development and validation of animal models and ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological or neuromuscular disorder
- Participating Institute: NINDS
- To apply: PAR-21-123
Funding for Preclinical/Clinical Development
National Cooperative Drug Discovery/Development Groups (NCDDG)
- Support: Up to 5 years of funding for multidisciplinary teams, Public Private Partnerships
- Participating Institutes: NIMH, NIAAA, NIDA
- To apply: PAR-20-118 (U01), PAR-20-119 (U19)
Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)
- Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
- Participating Institute: NIAAA
- To apply: PAR-18-580 (UT2 - Clinical Trial Optional)
Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)
- Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
- Participating Institute: NIAAA
- To apply: PAR-18-578 (U44 - Clinical Trial Optional)
Strategic Alliances for Medications Development to Treat Substance-Use Disorders
- Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
- Participating Institute: NIDA
- To apply: PAR-19-318 (R01)
Grand Opportunities in Medications Development for Substance-Use Disorders
- Support: Up to 3 years of funding, milestone-driven, up to $5M per year
- Participating Institute: NIDA
- To apply: PAR-19-327 (U01)
Alzheimer's Drug-Development Program
- Support: Up to 5 years of funding, milestone-driven, up to $1M per year
- Participating Institute: NIA
- To apply: PAR-18-820 (U01)
Services
Services for Pharmacology
Epilepsy Therapy Screening Program (ETSP)
- Support: Screens compounds in animal seizure models
- To apply: Contact Brian Klein, Ph.D.
Addiction Treatment Discovery Program (ATDP)
- Support: Screens compounds in animal models of addiction
- To apply: Contact David White, Ph.D., (301) 443-8889
Services for Toxicology
Bridging Interventional Development Gaps (BrIDGs)
- Support: Provides synthesis, formulation, pharmacokinetic and toxicology expertise and resources to its collaborators and is open to any disease.
- To apply: See the National Center for Advancing Translational Sciences (NCATS) for more information.
NIDA Toxicology Program
- Support: Provides IND-directed toxicology services for substance abuse indications.
- To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475
Regulatory Affairs Assistance for Medications Development
- Support: Provides consultation and advice on regulatory requirements
- Participating Institute: NIDA
- To apply: Contact Robert Walsh, R.A.C.
BPN-Biologics Staff
Program Director
Dr. Mario SkiadopoulosHealth Program Specialists
Ms. Elena Barnaeva
Ms. Shruthi ThomasProject ManagerOperations Coordinator
Ms. Natasha Davis